Full history for every metric is available with a Kvantra account
Nichi-Iko Pharmaceutical Co., Ltd. (4541.T)
Key financial summary
Financials in JPY| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥tn | 0 | 16 | 0 | 0 | 0 | 17 | 21 |
| Operating profit | ¥tn | 1 | 1 | |||||
| Net profit | ¥tn | 0 | 1 | 0 | -0 | -0 | 1 | 1 |
| EPS reported | ¥ | 128.0 | 263.3 | |||||
| Operating cashflow per share | ¥ | 418.4 | 418.4 | |||||
| Capex per share | ¥ | 93.35 | 93.35 | |||||
| FCF per share | ¥ | 325.0 | 325.0 | |||||
| Free cash flow | ¥tn | 2 | 0 | |||||
| Net debt | ¥tn | 0 | 1 | |||||
| Book value equity | ¥tn | 10 | 10 | |||||
| Book value per share | ¥ | 1,978 | 2,030 | |||||
| Number of shares | m | 5,088.92 | 5,088.92 | |||||
| DPS (TTM paid) | ¥ | 41.95 | 0.00 |
Financial summary
Financials in JPY| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 0.21 | - | |||||
| P/B LTM | x | 0.01 | 0.00 | |||||
| P/S LTM | x | 0.01 | 0.00 | |||||
| P/FCF LTM | x | 0.08 | 0.01 | |||||
| EV/EBITDA LTM | x | 0.33 | 0.42 | |||||
| EV/Sales LTM | x | 0.04 | 0.03 | |||||
| Earnings Yield LTM | % | 476.19% | 365.73% | |||||
| FCF Yield | % | 1226.9% | 17512.1% | |||||
| Quality | ||||||||
| ROE | % | 6.47% | 12.93% | |||||
| ROIC | % | 7.89% | 7.89% | |||||
| Operating margin | % | 4.62% | 4.62% | |||||
| Gross margin | % | 19.70% | 19.70% | |||||
| FCF/Sales | % | 9.78% | 9.78% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +9342.5% | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 158.36% | 0.00% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | 32.77% | 15.09% | |||||
| FCF/Debt | x | 0.38 | 0.09 | |||||
| Net Debt/EBITDA | x | 0.27 | 0.27 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | 227.79% | 23459.6% | |||||
| Net debt/Equity | x | 0.03 | 0.06 | |||||
| Gross debt/equity | x | 0.43 | 0.47 | |||||
Company overview
Nichi-Iko Pharmaceutical Co., Ltd. actively manufactures, distributes, imports, and sells a wide variety of pharmaceutical products. Operating through its Sagent Group and Nichi-Iko Group segments, the company primarily focuses on the development and production of generic drugs. Its extensive product line encompasses antidiabetic, antacid, and antireflux agents, as well as beta-blockers, hypnotics, sedatives, angiotensin II antagonists (including combinations with diuretics), dyslipidemic agents, and calcium antagonists. These offerings target conditions affecting the circulatory, digestive, respiratory, central, and peripheral nervous systems, among others. Beyond pharmaceuticals, the company is also involved in packaging design and exports its products internationally. Established in 1947 as Nihon Iyakuhin Kogyo Co., Ltd., the firm officially became Nichi-Iko Pharmaceutical Co., Ltd. in 2005 and is headquartered in Toyama, Japan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Nichi-Iko Pharmaceutical Co., Ltd. (4541.T)
Nichi-Iko Pharmaceutical Co., Ltd. actively manufactures, distributes, imports, and sells a wide variety of pharmaceutical products. Operating through its Sagent Group and Nichi-Iko Group segments, the company primarily focuses on the development and production of generic drugs. Its extensive product line encompasses antidiabetic, antacid, and antireflux agents, as well as beta-blockers, hypnotics, sedatives, angiotensin II antagonists (including combinations with diuretics), dyslipidemic agents, and calcium antagonists. These offerings target conditions affecting the circulatory, digestive, respiratory, central, and peripheral nervous systems, among others. Beyond pharmaceuticals, the company is also involved in packaging design and exports its products internationally. Established in 1947 as Nihon Iyakuhin Kogyo Co., Ltd., the firm officially became Nichi-Iko Pharmaceutical Co., Ltd. in 2005 and is headquartered in Toyama, Japan.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free